Originally published Monday, October 6, 2008 at 12:00 AM
Comments (0)
E-mail article
Print view
Dendreon shares leap on mixed news for Provenge
Dendreon's interim results from a trial of its prostate-cancer drug Provenge show mixed results, but stock soars anyhow.
Seattle Times business reporter
Dendreon said Monday that Provenge demonstrably improved survival among prostate cancer patients, according to long-awaited interim results from a clinical trial.
The results sent Dendreon shares soaring, but were not strong enough for the company to ask federal regulators for speedier approval. Instead, the Seattle biotech firm will await the final analysis, scheduled for mid-2009.
The news is "not as good as it could have been, nor as bad as it could have been," said Paul Latta, an analyst with McAdams Wright Ragen.
Dendreon shares traded at $6.93, up 33 percent, after jumping as high as $9 in early morning trading, against the dismal backdrop painted by a global financial shakeout.
Provenge, Dendreon's lead therapy, which would be the first commercial immunetherapy to fight cancer, if it is approved.
But it has been a roller-coaster ride for many investors. In early 2007 the company stock rode as high as $19 on hopes that the U.S. Food and Drug Administration would approve the product in May of that year.
But the agency decided to withhold approval, asking for more data instead. That triggered a sharp fall in the stock price and an angry response from prostate cancer patients eager for a promising treatment.
Hopes soared again when the FDA said it would look at the interim data presented today as sufficient to support an application for approval. But the data "did not meet the pre-specified criteria" for Dendreon to modify the marketing approval it has pending at the FDA, said Chief Executive Mitch Gold in a conference call.
In order to meet its goals, Dendreon needs to demonstrate a 22 percent reduction in the risk of death among patients using Provenge, based on 304 patients, the company said.
The final analysis of the data was originally due in 2010, but the last March company redesigned the clinical trial in order to fast-forwards the results by a year.
Ángel González: 206-515-5644 or agonzalez@seattletimes.com
Copyright © 2008 The Seattle Times Company
More Business & Technology headlines...
E-mail article
Print view Share:
Digg
Newsvine
![]()
NEW - 12:18 AM
Microsoft CFO to exit after tough year of cost-cutting
St. Louis exec now boss of all Boeing giving
Saab's fate uncertain after deal collapses
Reform won't take bite out of health-care profits
Facebook's new share structure hints at public offering

New Beginnings Christian Fellowship
Coming in this Sunday's Pacific Northwest Magazine: Pastor Braxton's mission is to preach a message that appeals to everyone.
nwautos
Local riders say they've seen a surge in scooter interest in recent years, mostly from people wanting another commuting option. Seattle now ranks as o...
Post a comment
nwjobs
Post a comment
Michelle Goodman blogs about work/life balance.
Do you suffer from "sitting disease"?
Post a comment
- Home break-in ends in shootings, Everett police say
- Steve Kelley | Next Seahawks GM should be Mike Holmgren
- Mariners Blog | Jose Lopez appears to be on his way out
- Illegal workers quietly let go
- Amazon, Wal-Mart escalate Web price war
- As glam as he wants to be: Adam Lambert's real debut
- Sprouts, raw fish on attorney's 'do not eat' list
- Bellevue Blog | Bellevue residents blast new bikini espresso stand
- Big demand, grim outlook for state Basic Health Plan
- Husky Men's Basketball Blog | An interview with Enes Kanter's coach
- Bellevue residents blast new bikini espresso stand
254 - Jose Lopez appears to be on his way out
245 - Big demand, grim outlook for state Basic Health Plan
206 - Next Seahawks GM should be Mike Holmgren
155 - Washington State coach Paul Wulff says he's excited about Cougars' future
139 - Hate crimes against gays, religious groups up, FBI says
91 - Man shoots self at Westlake Center
83 - Some fans at Fort Bragg see themselves in Sarah Palin
82 - Teen pimp found guilty of human trafficking
66 - Portland cafe's specialty: medical-marijuana tokes
49
- Sprouts, raw fish on attorney's 'do not eat' list
- Tattoos at Mill Creek church pierce skin, soul
- Food-safety lawyer's wish: Put me out of business
- Illegal workers quietly let go
- Architects, chefs find 'kid' within to build Gingerbread Village
- Nicole Brodeur | Homeless woman bent on giving
- Portland cafe's specialty: medical-marijuana tokes
- Big demand, grim outlook for state Basic Health Plan
- Hutch gets $10M from Bezos family for immunotherapy research
- Rediscovering Moab, 'the most beautiful place on Earth'





